Clinical-stage therapeutic discovery and development company Compugen Ltd. (Nasdaq:CGEN) (TASE:CGEN) announced on Monday the FDA clearance of the IND application for COM503.
This high-affinity anti-IL-18 binding protein antibody, licensed to Gilead Sciences, Inc., will initiate a Phase 1 trial in Q4 2024. The IND clearance has triggered a USD30m milestone payment from Gilead.
The Phase 1 trial will evaluate the safety and tolerability of COM503 as a monotherapy and in combination with Gilead's zimberelimab in participants with advanced or metastatic solid tumors globally.
Dr Cohen-Dayag highlighted the significance of COM503, emphasizing its potential in cancer therapeutics and its discovery through Compugen's computational technology.
This milestone enhances Compugen's financial position, providing a cash runway into 2027. Preparations for the Phase 1 trial are well-advanced.
Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
Adaptive Biotechnologies and NeoGenomics partner to expand MRD monitoring for blood cancer
BioArctic reports FDA acceptance of BLA for for subcutaneous maintenance dosing of Leqembi
Elicera Therapeutics receives ODD for ELC-100
ReciBioPharm secures grant to expand RNA manufacturing in LMICs
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc